Statement: Candidates must have a life expectancy exceeding 3 months to particpate in the primary trial, there is no mimimum life expectancy define for the secondary trial.
Primary_evidence: Inclusion Criteria:   All tumors must be ER-, PR- and HER2-negative   Clinical stage T2 or T3, N0-3, M0. Subjects with inflammatory breast cancer are not eligible   For subjects with clinically negative axilla, a sentinel lymph node biopsy will be performed either up front or after preoperative therapy at the discretion of the subject's physicians; for subjects with a clinically positive axilla, a needle aspiration or core biopsy will be performed to confirm the presence of metastatic disease in the lymph nodes.   18 years of age or older   Performance status (PS) of 0 or 1   Use of an effective means of contraception in subjects of child-bearing potential   Normal organ function as described in the protocol Exclusion Criteria:   Any prior cytotoxic chemotherapy or radiation for the current breast cancer   HER2-negative ipsilateral breast recurrence, unless prior treatment consisted of excision alone for ductal carcinoma in situ (DCIS)or breast-conserving treatment and hormonal therapy for DCIS or invasive cancer   Life expectancy of less than 12 weeks   Current, recent, or planned participation in an experimental durg study other than a Genentech-sponsored bevacizumab cancer study   Renal dysfunction for which exposure to cisplatin would require dose modifications   Steroid dependent asthma   Peripheral neuropathy of any etiology that exceeds grade 1   Uncontrolled diabetes   History of malignancy treated without curative intent   Any other pre-existing medical condition that would represent toxicity in excess of grade 1   Inadequately controlled hypertension   Any prior history of hypertensive crisis or hypertensive encephalopathy   New York Heart Association (NYHA) Grade II or greater congestive hear failure   History of myocardial infarction or unstable angina within 12 months prior to study enrollment   Any history of stroke or transient ischemic attack at any time   Known central nervous system (CNS) disease   Significant vascular disease   Symptomatic peripheral vascular disease   Evidence of bleeding diathesis or coagulopathy   Major surgical procedure, open biopsy, or significant traumatic injury within 21 days prior to study enrollment   History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months prior to study enrollment   Serious, non-healing wound, ulcer or bone fracture   Proteinuria at screening   Known hypersensitivity to any component of bevacizumab   Pregnant or lactating
Secondary_evidence: Inclusion Criteria:   Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (ECOG performance status of 2 will be allowed if only due to debilitating bone disease)   HER2-positive metastatic or locally advanced breast cancer   For MBC participants:   Documented metastatic or inoperable locally advanced (without meeting LABC criteria) disease, amenable for treatment with docetaxel   History of disease progression within 3 months prior to study entry   For LABC participants:   Newly diagnosed locally advanced breast cancer, Stage IIA-IIIC (American Joint Committee on Cancer [AJCC] staging system) Exclusion Criteria:   Significant cardiac disease   Inadequate bone marrow, liver or renal function   For MBC participants:   Participants must not have received radiotherapy for the treatment of metastatic or locally recurrent/advanced disease other than for the relief of pain in progressing metastatic bone lesions and/or brain metastases   Brain metastases that are untreated, symptomatic or require therapy to control symptoms; or any radiation, surgery, or other therapy to control symptoms from brain metastasis within 2 months of the first study treatment.   For LABC participants:   Clinically or radiologically detectable metastasis (M1 disease)   Participants for whom surgery as primary intent procedure is the best option to treat their disease   Participants must not have received any systemic or loco-regional anti-cancer therapy for the treatment of locally advanced disease